Passa al contenuto
Merck
Tutte le immagini(1)

Key Documents

View All Documentation

1724088

USP

Zanamivir

United States Pharmacopeia (USP) Reference Standard

Sinonimo/i:

4-Guanidino-2,4-dideoxy-2,3-dehydro-N-acetylneuraminic acid, 4-Guanidino-Neu5Ac2en

Autenticatiper visualizzare i prezzi riservati alla tua organizzazione & contrattuali
Tutte le immagini(1)

About This Item

Formula empirica (notazione di Hill):
C12H20N4O7
Numero CAS:
139110-80-8
Peso molecolare:
332.31
Numero MDL:
MFCD00866966
Codice UNSPSC:
41116107
ID PubChem:
329751520
NACRES:
NA.24

Grado

pharmaceutical primary standard

Famiglia di API

zanamivir

Produttore/marchio commerciale

USP

applicazioni

pharmaceutical (small molecule)

Formato

neat

Temperatura di conservazione

2-8°C

Stringa SMILE

CC(=O)N[C@@H]1[C@@H](NC(N)=N)C=C(O[C@H]1[C@H](O)[C@H](O)CO)C(O)=O

InChI

1S/C12H20N4O7/c1-4(18)15-8-5(16-12(13)14)2-7(11(21)22)23-10(8)9(20)6(19)3-17/h2,5-6,8-10,17,19-20H,3H2,1H3,(H,15,18)(H,21,22)(H4,13,14,16)/t5-,6+,8+,9+,10+/m0/s1
ARAIBEBZBOPLMB-UFGQHTETSA-N

Cerchi prodotti simili? Visita Guida al confronto tra prodotti

Descrizione generale

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Applicazioni

Zanamivir USP reference standard, intended for use in specified quality tests and assays as specified in the USP compendia.

Azioni biochim/fisiol

Zanamivir is an influenza viral neuraminidase inhibitor.

Risultati analitici

These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.  ​

Altre note

Sales restrictions may apply.

Pittogrammi

Exclamation mark
GHS07

Avvertenze

Warning

Indicazioni di pericolo

H302,H315,H319,H335

Classi di pericolo

Acute Tox. 4 Oral - Eye Irrit. 2 - Skin Irrit. 2 - STOT SE 3

Organi bersaglio

Respiratory system

Codice della classe di stoccaggio

11 - Combustible Solids

Classe di pericolosità dell'acqua (WGK)

WGK 3

Punto d’infiammabilità (°F)

Not applicable

Punto d’infiammabilità (°C)

Not applicable

Certificati d'analisi (COA)

Cerca il Certificati d'analisi (COA) digitando il numero di lotto/batch corrispondente. I numeri di lotto o di batch sono stampati sull'etichetta dei prodotti dopo la parola ‘Lotto’ o ‘Batch’.

Possiedi già questo prodotto?

I documenti relativi ai prodotti acquistati recentemente sono disponibili nell’Archivio dei documenti.

Visita l’Archivio dei documenti

I clienti hanno visto anche

Slide 1 of 6

1 of 6

Ribavirin Pharmaceutical Secondary Standard; Certified Reference Material

Supelco

PHR1700

Ribavirin

Mupirocin United States Pharmacopeia (USP) Reference Standard

USP

1448901

Mupirocin

Tobramicina United States Pharmacopeia (USP) Reference Standard

USP

1667508

Tobramicina

N-Acetyl-2,3-dehydro-2-deoxyneuraminic acid ≥93% (TLC)

Sigma-Aldrich

D9050

N-Acetyl-2,3-dehydro-2-deoxyneuraminic acid

Ribavirin antiviral

Sigma-Aldrich

R9644

Ribavirin

Mucin from bovine submaxillary glands Type I-S

Sigma-Aldrich

M3895

Mucin from bovine submaxillary glands

Susan Barrett et al.
Antiviral research, 108, 30-35 (2014-05-24)
The influenza virus neuraminidase inhibitors are normally slow binding inhibitors, but many mutations leading to resistance, also result in the loss of the slow binding phenotype. Mutations can also affect the rate of dissociation of the inhibitors from the neuraminidase
Kristin A Gabor et al.
Disease models & mechanisms, 7(11), 1227-1237 (2014-09-06)
Seasonal influenza virus infections cause annual epidemics and sporadic pandemics. These present a global health concern, resulting in substantial morbidity, mortality and economic burdens. Prevention and treatment of influenza illness is difficult due to the high mutation rate of the
Alireza Eshaghi et al.
Antimicrobial agents and chemotherapy, 58(12), 7188-7197 (2014-09-24)
Immunocompromised patients are predisposed to infections caused by influenza virus. Influenza virus may produce considerable morbidity, including protracted illness and prolonged viral shedding in these patients, thus prompting higher doses and prolonged courses of antiviral therapy. This approach may promote
Xiaoli Xiong et al.
Virology, 456-457, 179-187 (2014-06-04)
Mutant H5N1 influenza viruses have been isolated from humans that have increased human receptor avidity. We have compared the receptor binding properties of these mutants with those of wild-type viruses, and determined the structures of their haemagglutinins in complex with
Ken Watanabe et al.
Archives of medical research, 45(5), 359-365 (2014-06-01)
Influenza viruses are a serious threat to human health and cause thousands of deaths annually. Thus, there is an urgent requirement for the development of novel anti-influenza virus drugs. Therefore, the aim of this study was to evaluate the anti-influenza
Visualizza tutti i documenti correlati

Il team dei nostri ricercatori vanta grande esperienza in tutte le aree della ricerca quali Life Science, scienza dei materiali, sintesi chimica, cromatografia, discipline analitiche, ecc..

Contatta l'Assistenza Tecnica.